All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
A phase II study investigated the use of coltuximab ravtansine (SAR3419) in patients with relapsed refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study was published in Haematologica by Marek Trněný, Head of the 1st Department of Internal Medicine at Charles University, Prague, and colleagues on 10 May 2018.
The study was single-arm and multi-center assessing the safety and efficacy of SAR3419 in patients who had been previously treated with rituximab-containing immunochemotherapy. SAR3419 is an anti-CD29 antibody-drug conjugated to DMR, a cytotoxic maytansinoid. It has shown clinical benefit in previous phase I studies and a maximum tolerated dose (MTD) was identified as 55 mg/m2.
The authors concluded that SAR3419 demonstrated a moderate clinical response in R/R DLBCL patients with an acceptable toxicity profile. They also observed that the response rates were lower in patients who were refractory to previous treatment. A further study with a higher number of patients could be beneficial to conduct further analysis.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox